NCT07328087 — Biogenea Pharmaceuticals neoantigen vaccine trial
COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer
Registry record
| Registry ID | NCT07328087 ↗ |
|---|---|
| Lead sponsor | Biogenea Pharmaceuticals Ltd. |
| Collaborators | Interbalkan Medical Center, Thessaloniki, Greece |
| Phase | Phase EARLY_PHASE1 |
| Status | Recruiting |
| Indication | Colorectal Cancer Metastatic, Colorectal Cancer Stage III, Colorectal Cancer Stage IV |
| Enrollment | 12 participants (target) |
| Start date | 2026-02-02 |
| Primary completion | 2030-12-02 (est.) |
| Last registry update | 9 Jan 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT07328087), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT07328087?
NCT07328087 (COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer) is registered on ClinicalTrials.gov as Phase EARLY_PHASE1, sponsored by Biogenea Pharmaceuticals Ltd..
Is NCT07328087 recruiting?
As of the 2026-01-09 registry update, NCT07328087 is listed as "Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT07328087?
The lead sponsor is Biogenea Pharmaceuticals Ltd.. Collaborators: Interbalkan Medical Center, Thessaloniki, Greece.
What condition does NCT07328087 study?
The registered conditions are Colorectal Cancer Metastatic, Colorectal Cancer Stage III, Colorectal Cancer Stage IV. Primary completion is listed as 2030-12-02 (estimated).
Are results available for NCT07328087?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT07328087.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.